Terns Pharmaceuticals ( (TERN) ) has issued an announcement.
On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew Gengos as Chief Financial Officer, effective February 24, 2025. Mr. Gengos brings 25 years of experience in finance and corporate strategy within the biotechnology industry, having held senior roles at companies such as Athira Pharma and Cyteir Therapeutics. This strategic appointment is expected to bolster Terns’ financial leadership as it advances its oncology and obesity programs. The transition also involves Amy Burroughs and David Strauss stepping down from their roles as principal financial officer and principal accounting officer, respectively, while continuing in other capacities within the company.
More about Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focusing on developing small-molecule product candidates to address serious diseases, including oncology and obesity. Their pipeline includes clinical stage development programs such as an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort.
YTD Price Performance: -29.37%
Average Trading Volume: 1,818,795
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $340.2M
For detailed information about TERN stock, go to TipRanks’ Stock Analysis page.